1 documents found
Information × Registration Number 0120U104462, R & D request Title A multicenter, randomized, double-blind, controlled phase 3b study to evaluate the efficacy and safety of subcutaneous guselcumab in patients with active psoriatic arthritis and insufficient response to tumor necrosis factor alpha (anti-TNF-alpha) antagonists. Head Tkachenko Maksym V., Registration Date 21-10-2020 Organization Ukrainian medical stomatological Academy popup.description1 phase 3c study to evaluate the efficacy and safety of subcutaneous guselcumab in patients with active psoriatic arthritis and insufficient response to tumor necrosis factor alpha antagonist (anti-TNF-alpha) antagonists popup.nrat_date 2024-12-10 Close
search.res_rk
A multicenter, randomized, double-blind, controlled phase 3b study to evaluate the efficacy and safety of subcutaneous guselcumab in patients with active psoriatic arthritis and insufficient response to tumor necrosis factor alpha (anti-TNF-alpha) antagonists.
Head: Tkachenko Maksym V.. A multicenter, randomized, double-blind, controlled phase 3b study to evaluate the efficacy and safety of subcutaneous guselcumab in patients with active psoriatic arthritis and insufficient response to tumor necrosis factor alpha (anti-TNF-alpha) antagonists.. Ukrainian medical stomatological Academy. № 0120U104462
1 documents found

Updated: 2026-03-26


Роздрукувати цю сторінку